Respiratory Inhalers Market USD 33,572.9 Million Revenue, Industry Size, Competitive Analysis, Business Overview and Regional Forecasts To 2023

Respiratory Inhalers Market
Market Research Future published a Cooked Research Report on “Global Respiratory Inhalers Market Research Report – Forecast to 2023” – Market Analysis, Scope, Stake, Progress, Trends and Forecast to 2023

Global Respiratory Inhalers Market – Overview

Respiratory inhalers are medical devices that are used to assist a patient encountering breathing problems resulting from respiratory disorders such as fibrosis, asthma, COPD and ARDS and others. There are some major drivers, driving the market growth such as rising prevalence of respiratory disorders due to increase pollution and unhealthy lifestyle, increasing usage of combination therapies due to associated benefits such as more reliable in complex patients, increased efficacy and easy reimbursement policies associated with them and others. Various restraints, which are restricting the market growth includes side effects and complications during inhalation, high prices of devices, and lack of accuracy etc.

Adherium limited, AstraZeneca, Boehringer Ingelheim GmbH, Chiesi Farmaceutici S.p.A., GSK plc, Propeller Health, and Teva Pharmaceutical Industries Ltd are some of the prominent players at the forefront of competition in the Global Respiratory Inhalers Market and are profiled in MRFR Analysis.

Get Exclusive Sample Report @ .

​​​​​​​It is observed during recent years that patients are shifting towards combined therapies such as bronchodilator therapy for the treatment of COPD and various others, due to accompanying benefits such as more reliable in complex patients, increased efficacy and easy reimbursement policies linked with therapy. It is also observed that these combination therapies are more affective for long term control of COPD and other respiratory diseases. These therapies cost more compared to conventional therapies for patients with complex signs of respiratory disease or disorders. Increase in usage of combination therapies such as triple combination therapy for COPD patients is expected to drive the growth of the global respiratory inhaler devices market in coming years.

Global Respiratory Inhalers Market – Competitive Analysis

February, 2017 – Adherium’s partnering and market expansion for the ‘Rest of World’ territories, including countries in Asia Pacific and the Middle East where Adherium already has sanctions to market its Smart inhaler products in China, Australia and New Zealand. This has increased the company’s strength in these countries.

January, 2017 – AstraZeneca had announced that on 25 January 2017 the US Food and Drug Administration (FDA) granted six months of paediatric exclusivity for Symbicort (budesonide/formoterol) Inhalation Aerosol. Symbicort is approved in the US to treat asthma in patients 12 years and older and for the maintenance and treatment of COPD in adults, the company is expecting larger market share with the product launch.

Global Respiratory Inhalers Market – Regional Analysis

Respiratory inhalers market is segmented on the basis of geographies or regions which mainly includes North America, Europe, Asia Pacific, and Rest of the world. Currently the largest market share of global respiratory inhalers market is captured by North America, majorly due to large population among adult and kids being diagnosed with the disease like asthma and COPD in the region. U.S. accounts for the largest market share of North America respiratory inhalers market. This large share is majorly due to, tobacco smoke which is a key factor in the development and progression of COPD. Apart from this, genetic factors and respiratory infections also play a role. COPD was considered the third leading cause of death in U.S. in 2014, with almost 6.4% of Americans diagnosed with the disease. Europe, accounts for the second largest, in the global respiratory inhalers market, majorly due to companies or the key players present in the region such as, Novartis, AstraZeneca, and Boehringer Ingelheim. Adoption of respiratory inhalers by hospitals and patients in the European countries, and also due to continuous efforts made by European Academy of Allergy & Clinical Immunology to increase awareness about asthma and COPD the market for respiratory inhalers is expected to show grow in the coming future. Asia-Pacific region is estimated to be the fastest growing market due to continuous developments in developing countries like India and China. Emerging economies are expected to accounts for the maximum cases of respiratory disorders, remains unnoticed. High prevalence of these disease due to tobacco smoke, exposure to air pollutants in the home and workplace, vehicular pollution, indoor air pollution from biological agents related to damp and mould further increases the risk of respiratory disease in children and adults in these countries. Moreover, significant growth in the digitally operated inhalers is observed in the countries like Australia and New Zealand. On the other hand, the Middle East & Africa have the least market share. Additionally, factors such as lack of awareness, low healthcare expenditures will restrain the market during the corresponding period.

Get Your Customized Report @ .

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Media Contact
Company Name: Market Research Future
Contact Person: Abhishek Sawant
Email: Send Email
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar
City: Pune
State: Maharashtra
Country: India